Abstract
Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have